HALIFAX, April 17, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, announced today that Company co-founder and CEO, Hermes Chan, will be speaking at the Innovation and Technology Day (ITD) in Doha, Qatar on April 24, 2012. ITD, an open forum for technology pioneers, entrepreneurs, policy makers, and experts, designed to facilitate the dialogue and action on key issues related to innovation, technology and development, is a joint initiative of the United Nations Conference on Trade and Development and the Qatar Foundation.
Mr. Chan will take the stage to speak about the inspiration behind MedMira and his experiences in creating and commercializing Company's patented rapid diagnostics technology platform and diagnostic applications as well as the impact of these innovations on both healthcare and economic growth in developing countries. The audience will be composed of members of Diplomatic Delegations and Government officials from many countries as well as individuals from the network of universities and research centers of the Qatar Foundation.
"It is a privilege to be invited to speak at UNCTAD XIII about innovation, something which I am very passionate about and which is at the heart of everything we have done and continue to accomplish at MedMira," said Hermes Chan, CEO, MedMira. "Sharing the MedMira vision in this world class international forum is a great honor and an exciting opportunity to build key relationships with organizations such as UNCTAD, the Qatar Foundation, and other agencies working to further economic sustainability in developing countries through innovation and technology."
ITD is part of the thirteenth session of the United Nations Conference on Trade and Development (UNCTAD XIII) taking place April 21-26, 2012 in Doha, Qatar. Within the United Nations system, UNCTAD is the focal point for the integrated treatment of trade and development and the interrelated issues in the areas of finance, technology, investment, and sustainable development. To learn more visit www.innotechday.org.
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics and technologies. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible future growth and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information: